A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
Study sponsor: Karyopharm Therapeutics Inc · KPTI
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-01Estimated
Enrollment · participants127Estimated
Source updated2026-10-29Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.